Currently, several predicting models incorporating clinical features and viral factors (e.g., serum levels of HBV DNA, HBeAg, and HBsAg) have been developed to evaluate the risk of HCC development in CHB patients [21], with periodic screening using ultrasonography with alpha-fetoprotein (AFP) among high-risk groups the most frequently used strategy for early detection of HBV-HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.